GoldenGolden
Akouos

Akouos

Akouos is a Brookline, Massachusetts-based biotechnology company developing precision genetics-based medicines founded in 2016 by Emmanuel Simons.

Akouos is a biotechnology company and developer of precision genetic medicine to restore and preserve hearing in the hearing impaired.

Timeline

June 8, 2020
Akouos eyes an initial public offering valued at about $100 million.

March 31, 2020
Akouos raises a $105,000,000 series B round.
March 31, 2020
Akouos raises a $105,000,000 series B round from Pivotal bioVenture Partners.
August 2018
Akouos raises a $50,000,000 series A round from 5AM Ventures, New Enterprise Associates, Novartis Venture Fund, Partners Innovation Fund, RA Capital Management and Sofinnova Ventures.
November 30, 2017
Akouos raises a $7,500,000 seed round.
November 30, 2017
Akouos raises a $7,500,000 seed round from 5AM Ventures.
2016
Akouos was founded by Emmanuel Simons.

Funding rounds

People

Name
Role
LinkedIn

Further reading

Title
Author
Link
Type
Date

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

News

Title
Author
Date
Publisher
Description
Mark Terry
May 11, 2021
BioSpace
The 24th Annual meeting of the American Society of Gene & Cell Therapy presents cutting-edge work in the booming area of gene and cell therapy. Here's a look at a few of the highlights.
BioSpace
May 11, 2021
BioSpace
- Intracochlear delivery of a dual AAVAnc80 vector encoding human otoferlin results in full-length protein expression in inner hair cells of non-human primates and in durable protein expression sufficient for sustained restoration of auditory function in Otof knockout mice
BioSpace
May 7, 2021
BioSpace
Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced the appointment of Dr. Kathy Reape as chief development officer.
BioSpace
April 13, 2021
BioSpace
Akouos, Inc. (NASDAQ: AKUS), a precision genetic medicine company dedicated to developing potential gene therapies for individuals living with disabling hearing loss worldwide, today announced that the U.S. Food and Drug Administration (FDA) has granted both Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) for AK-OTOF, a gene therapy intended for the treatment of otoferlin gene-mediated hearing loss.
Alex Keown
June 8, 2020
BioSpace
Three months after hearing loss-focused company Akouos secured $105 million in a Series B financing round, the Boston-based company is eying an initial public offering valued at about $100 million.
Ben Adams
June 8, 2020
FierceBiotech
Boston-based hearing loss gene therapy biotech Akouos is gunning for a $100 million IPO amid a near invulnerable market for public-seeking biotechs.
Nick Paul
May 19, 2020
FierceBiotech
Cowen Healthcare Investments has raised a $493 million fund, breezing past its original goal by close to $100 million. The fund closure positions Cowen to continue following an investment strategy that has seen it invest in biotechs such as Akouos, AM-Pharma and Keros Therapeutics in recent months.

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.